Tarsus Pharmaceuticals (TARS) Equity Ratio (2019 - 2026)

Tarsus Pharmaceuticals' Equity Ratio history runs 8 years deep, the most recent figure standing at 0.6 for Q1 2026.

• In Q1 2026, Equity Ratio fell 12.2% year-over-year to 0.6; the TTM figure through Mar 2026 stood at 0.6 (down 12.2% YoY), while the FY2025 annual figure was 0.61, up 2.57% from the prior year.
• Equity Ratio was 0.6 for Q1 2026 at Tarsus Pharmaceuticals, down from 0.61 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.88 in Q2 2022 to a low of 0.6 in Q4 2024.
• Historically, Equity Ratio has averaged 0.73 across 5 years, with a median of 0.74 in 2023.
• The sharpest annual moves came in 2024 and 2025: Equity Ratio fell 20.74% in 2024, then climbed 2.57% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.85 in 2022, then dropped by 12.35% to 0.74 in 2023, then retreated by 19.73% to 0.6 in 2024, then grew by 2.57% to 0.61 in 2025, then fell by 1.71% to 0.6 in 2026.
• The last three Equity Ratio figures came in at 0.6 (Q1 2026), 0.61 (Q4 2025), and 0.63 (Q3 2025), per Business Quant data.